Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

(2017) S. E. Coutre et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

(2012) Joseph J. Buggy et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

(2011) A. Hadzidimitriou et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

B-cell receptor signaling in chronic lymphocytic leukemia

(2011) F. K. Stevenson et al.   BLOOD

Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man

(2011) Rudi W Hendriks et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Malignant pirates of the immune system

(2011) Lixin Rui et al.   NATURE IMMUNOLOGY

Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia

(2011) Jan A. Burger   Current Hematologic Malignancy Reports

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor

(2010) Fabienne Mackay et al.   IMMUNOLOGICAL REVIEWS

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesis

(2010) Anders Rosén et al.   SEMINARS IN CANCER BIOLOGY

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA

(2008) C. C. Chu et al.   BLOOD

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation

(2008) P. Ghia et al.   JOURNAL OF INTERNAL MEDICINE